Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 134

Sort by

Sort Order Select

Journal Articles

BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms

Holly Lee, Paola Neri, Nizar J. Bahlis

Blood (2024) 143 (13): 1211–1217.

https://doi.org/10.1182/blood.2023022499

Published: 2024

Includes: Supplemental data

Journal Articles

“Treatment with curative intent”: the emergence of genetic therapies for sickle cell anemia

Edward J. Benz, Jr., Leslie E. Silberstein, Julie Panepinto

Blood (2024) 143 (11): 967–970.

https://doi.org/10.1182/blood.2023021598

Published: 2024

Journal Articles

Recent developments in the use of pyruvate kinase activators as a new approach for treating sickle cell disease

Dina S. Parekh, William A. Eaton, Swee Lay Thein

Blood (2024) 143 (10): 866–871.

https://doi.org/10.1182/blood.2023021167

Published: 2024

Journal Articles

CAR T-cell therapy in multiple myeloma: mission accomplished?

Leo Rasche, Michael Hudecek, Hermann Einsele

Blood (2024) 143 (4): 305–310.

https://doi.org/10.1182/blood.2023021221

Published: 2024

Journal Articles

Macrophage heterogeneity in the single-cell era: facts and artifacts

David A. Hume, Susan M. Millard, Allison R. Pettit

Blood (2023) 142 (16): 1339–1347.

https://doi.org/10.1182/blood.2023020597

Published: 2023

Journal Articles

Pirtobrutinib: a new hope for patients with BTK inhibitor–refractory lymphoproliferative disorders

Philip A. Thompson, Constantine S. Tam

Blood (2023) 141 (26): 3137–3142.

https://doi.org/10.1182/blood.2023020240

Published: 2023

Includes: Supplemental data

Journal Articles

Tumor microenvironment contribution to checkpoint blockade therapy: lessons learned from Hodgkin lymphoma

Antonino Carbone, Annunziata Gloghini, Carmelo Carlo-Stella

Blood (2023) 141 (18): 2187–2193.

https://doi.org/10.1182/blood.2022016590

Published: 2023

Journal Articles

Vaccine-induced immune thrombotic thrombocytopenia

Douglas B. Cines, Andreas Greinacher

Blood (2023) 141 (14): 1659–1665.

https://doi.org/10.1182/blood.2022017696

Published: 2023

Journal Articles

Minimal information for reporting a genomics experiment

Kostiantyn Dreval, Paul C. Boutros, Ryan D. Morin

Blood (2022) 140 (24): 2549–2555.

https://doi.org/10.1182/blood.2022016095

Published: 2022

Includes: Supplemental data

Journal Articles

MRD in multiple myeloma: does CR really matter?

Bruno Paiva, Jesus San-Miguel, Hervé Avet-Loiseau

Blood (2022) 140 (23): 2423–2428.

https://doi.org/10.1182/blood.2022016170

Published: 2022

Journal Articles

Daratumumab in AL amyloidosis

Ashutosh D. Wechalekar, Vaishali Sanchorawala

Blood (2022) 140 (22): 2317–2322.

https://doi.org/10.1182/blood.2021014613

Published: 2022

Journal Articles

Hemolysis, free hemoglobin toxicity, and scavenger protein therapeutics

Florence Vallelian, Paul W. Buehler, Dominik J. Schaer

Blood (2022) 140 (17): 1837–1844.

https://doi.org/10.1182/blood.2022015596

Published: 2022

Journal Articles

Avapritinib for advanced systemic mastocytosis

Jason Gotlib, Andreas Reiter, Daniel J. DeAngelo

Blood (2022) 140 (15): 1667–1673.

https://doi.org/10.1182/blood.2021014612

Published: 2022

Journal Articles

Inflammation and myeloid malignancy: quenching the flame

Ryan J. Stubbins, Uwe Platzbecker, Aly Karsan

Blood (2022) 140 (10): 1067–1074.

https://doi.org/10.1182/blood.2021015162

Published: 2022

Journal Articles

Anticoagulation in hospitalized patients with COVID-19

Lisa Baumann Kreuziger, Michelle Sholzberg, Mary Cushman

Blood (2022) 140 (8): 809–814.

https://doi.org/10.1182/blood.2021014527

Published: 2022

Journal Articles

The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma

Eleonora Calabretta, Mehdi Hamadani, Pier Luigi Zinzani, Paolo Caimi, Carmelo Carlo-Stella

Blood (2022) 140 (4): 303–308.

https://doi.org/10.1182/blood.2021014663

Published: 2022

Journal Articles

Approval of brexucabtagene autoleucel for adults with relapsed and refractory acute lymphocytic leukemia

Noelle V. Frey

Blood (2022) 140 (1): 11–15.

https://doi.org/10.1182/blood.2021014892

Published: 2022

Journal Articles

T-cell–redirecting bispecific antibodies in multiple myeloma: a revolution?

Philippe Moreau, Cyrille Touzeau

Blood (2022) 139 (26): 3681–3687.

https://doi.org/10.1182/blood.2021014611

Published: 2022

Journal Articles

Asciminib: a new therapeutic option in chronic-phase CML with treatment failure

David T. Yeung, Naranie Shanmuganathan, Timothy P. Hughes

Blood (2022) 139 (24): 3474–3479.

https://doi.org/10.1182/blood.2021014689

Published: 2022

Journal Articles

Pegcetacoplan for paroxysmal nocturnal hemoglobinuria

Gloria F. Gerber, Robert A. Brodsky

Blood (2022) 139 (23): 3361–3365.

https://doi.org/10.1182/blood.2021014868

Published: 2022

NARROW

BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms

“Treatment with curative intent”: the emergence of genetic therapies for sickle cell anemia

Recent developments in the use of pyruvate kinase activators as a new approach for treating sickle cell disease

CAR T-cell therapy in multiple myeloma: mission accomplished?

Macrophage heterogeneity in the single-cell era: facts and artifacts

Pirtobrutinib: a new hope for patients with BTK inhibitor–refractory lymphoproliferative disorders

Tumor microenvironment contribution to checkpoint blockade therapy: lessons learned from Hodgkin lymphoma

Vaccine-induced immune thrombotic thrombocytopenia

Minimal information for reporting a genomics experiment

MRD in multiple myeloma: does CR really matter?

Daratumumab in AL amyloidosis

Hemolysis, free hemoglobin toxicity, and scavenger protein therapeutics

Avapritinib for advanced systemic mastocytosis

Inflammation and myeloid malignancy: quenching the flame

Anticoagulation in hospitalized patients with COVID-19

The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma

Approval of brexucabtagene autoleucel for adults with relapsed and refractory acute lymphocytic leukemia

T-cell–redirecting bispecific antibodies in multiple myeloma: a revolution?

Asciminib: a new therapeutic option in chronic-phase CML with treatment failure

Pegcetacoplan for paroxysmal nocturnal hemoglobinuria

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only